NRSN Company Profile and Key Details

NRSN has shown mixed momentum, losing -0.97% over the past week and -14.29% over the past quarter, though year-to-date performance is up 32.64%. Short-term trend indicators are mixed aligned (SMA20 -3.22%, SMA50 -0.84%, SMA200 -30.26%). The stock’s 14-day RSI is 47.64 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.32% below its high and over 32.6% above its low. Average 10-day trading volume of 106.65 thousand shares is below the 3-month average of 150.15 thousand, indicating normal recent market interest.

NeuroSense Therapeutics Ltd. has 24.60 million shares outstanding. The public float is 12.54 million shares, elevated short interest at 2.84% of float. This equals 579.23 thousand shares. The short ratio is 2.55 days. Institutional investors hold 2.56% of the float. Insiders own 29.68%.

NeuroSense Therapeutics Ltd. generated EPS of -$0.58 over the past year. Five-year average earnings growth is 2.71%. Wall Street analysts project EPS growth of 28.41% annually over the next five years. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.10. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $3.00. The high target offers 1607.32% upside. The low target suggests 265.85% downside. The mean target is $12.78. This offers 1458.54% upside. NeuroSense Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended April 06, 2026, missed forecasts by 210.73%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -45.45% in April 07, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) closed at $0.82 USD, losing -$0.04 (-4.49%) from the previous close of $0.86. The stock is currently mid-range between its 52-week high and low $0.63 and $2.60. With a market capitalization of about $20.26 million, NeuroSense Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.58). Key stats such as the average daily volume over the past year has been around 149.55 thousand shares, in line with its 52-week average. Headquartered in Herzliya, None, NeuroSense Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alon Ben-Noon, the company employs approximately 17 people and listed since December 09, 2021. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares are up 32.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NeuroSense Therapeutics Ltd. trading at a premium to the broader market with a P/E of -3.24. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.25, suggesting 1391.36% upside. Our AI forecast model points to short-term strength (10.79% over two weeks), a medium-term fall (-37.91% over three months), and a longer-term gain (91.14% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that NeuroSense Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.79%, with price expected at $0.91 by June 11, 2026, within a range of $0.85 to $0.98 3-Month Outlook: Projected fall of -37.91%, reaching $0.51 by August 26, 2026, with a range of $0.45 to $0.55. 1-Year Outlook: Projected gain of 91.14%, with price at $1.57 by May 28, 2027, within a range of $0.00 to $0.00.

NeuroSense Therapeutics Ltd. trades at a P/E ratio of -3.24, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -13.52 indicating negative book value, which may reflect financial stress. The P/FCF stands at -10237.9, also below market averages.